"Separating contenders from
pretenders in breast cancer"

-- ASCO Post

"Blazes a trail in breast cancer"

-- Nature Biotechnology

"A glimpse into the future of
phase II drug development?"

-- NEJM

I-SPY Email List Sign-up

NEW!!! I-SPY PATIENT INFORMATION SITE. Visit: www.ispypatient.org

Featured News

Natera to Present Data from the BEATRICE and I-SPY2 Trials in Early-Stage TNBC and HR+/HER2- Breast Cancer at the 2022 AACR Annual Meeting Natera to Present Data from the BEATRICE and I-SPY2 Trials in Early-Stage TNBC and HR+/HER2- Breast Cancer at the 2022 AACR Annual Meeting

I-SPY in the News

April 11, 2022

Dr. Laura Esserman among recipients of 2020 Brinker Awards for Scientific Distinction Dr. Laura Esserman among recipients of 2020 Brinker Awards for Scientific Distinction

I-SPY in the News

October 1, 2020

Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial

Press Release

July 29, 2020

-- more news --

What is I-SPY?

The I-SPY series of trials are changing the way new treatments are developed for breast cancer, helping make available new, better and more personalized treatments, faster. At the heart of the I-SPY program is the ground-breaking I-SPY 2 platform trial for neoadjuvant treatment of locally advanced breast cancer.